Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience.
Saved in:
| Title: | Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience. |
|---|---|
| Authors: | Torres MB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Surgery, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, United States., Leung CH; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zoghbi M; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ingram D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zarzour MA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Scally CP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Hunt KK; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Conley A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Bishop AJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Guadagnolo BA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Farooqi A; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Mitra D; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nakazawa MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Araujo D; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Livingston A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ratan R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lazar AJ; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nassif Haddad EF; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Apr 30; Vol. 16, pp. 1567736. Date of Electronic Publication: 2025 Apr 30 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1567736 |
